Biomarker quantification for athletic performance enhancement
A comprehensive biomarker quantification approach integrating cardiac biomarkers, metabolomics, and lipoprotein profiles to evaluate and enhance athletic performance through personalized insights.
Overview
This innovative solution offers a cutting-edge approach to athletic performance evaluation by quantifying a combination of cardiac biomarkers, metabolomics, and lipoprotein profiles. By integrating these diverse markers, the solution provides high-quality, actionable insights that inform product development and enhance athletic performance outcomes. This multi-marker approach aims to unveil metabolic pathways crucial for personalized athletic performance monitoring and recommendations.
Technical specifications
Key features:
- Quantification of cardiac biomarkers such as Troponins I and T, Natriuretic peptides, Creatine Kinase, Galectin-3, and ST2, which correlate with cardiac remodeling in athletes.
- Integration of metabolomics, including NMR-based quantification of approximately 60 metabolites, to capture changes during athletic performance.
- Analysis of lipidome and lipoprotein profiles to assess metabolic impacts pre- and post-exercise.
- Application in both elite and recreational athletes, utilizing data from diverse sources such as "Je cours pour ma forme" and "Tor des Géants" events.
Technology readiness level
This solution is at Technology Readiness Level 6, indicating it has been tested in relevant environments and is ready for further validation and development in collaboration with industry partners.
About Université de Liège
Université de Liège is a comprehensive public research university with a broad academic portfolio and campuses centered at Sart‑Tilman and in the city, serving its region and international partners. For industry, co‑located laboratories sit alongside the CHU de Liège university hospital, enabling clinical and translational collaboration. The adjacent Liège Science Park hosts companies next to university research, fostering joint R&D and day‑to‑day interaction. Research is backed by competitive European and Belgian funding, including Horizon Europe, the national science foundation (F.R.S.–FNRS), and programs of the Walloon Region. Industry engagement is streamlined through Interface Entreprises; with Gesval, it handles IP protection, licensing, and investment to speed commercialization.
delivered to your inbox.